AI designs drugs in months, but India takes a year to approve trials while Australia and China take weeks
jajoosam · x · 2026-09-16
Soham Sankaran and Kiran Mazumdar-Shaw co-authored an op-ed in the Economic Times arguing that AI can now design and develop life-saving medicines in months, yet India takes about a year to approve clinical trials — while Australia and China approve in weeks.
They call for decentralizing India's trial framework to speed up approval and keep AI-driven biotech from flowing overseas.
More from Safety
- Anthropic's Doom Rhetoric Sets Up Regulatory Capture and Taxpayer Backstop, Critic Argues — AlexTensor · 2026-09-16
- Guardian: Why tech companies might be happy for us to believe AI will kill us all — nordicinst · 2026-09-16
- Meta's Muse agent is a standalone app, not an Instagram feature — with rocky internal test reports — Thirumalaivasan_GJ · 2026-09-16
- InceptionRAG: Dormant-Passage Poisoning Attack Hits 80%+ Success Against RAG Defenses — chaumian · 2026-09-16
- 72% of US healthcare leaders admit AI agents run without formal IT approval — HealthcareLdr · 2026-09-16
- Ben Todd publishes 3-part series accusing OpenAI and Anthropic of regulatory capture via 'pacing the frontier' — ben_j_todd · 2026-09-16